Centre Hospitalier Universitaire de Besancon
chu-besancon.frLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
445
Active
71
Phase 3
21
Total enrollment
810,781
Pipeline matrix
Showing 28 of 28 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Regorafenib | — | — | — | — | 3 | ||
| Bevacizumab | — | — | — | 5 | |||
| Aspirin | — | — | — | — | 2 | ||
| Metronomic chemotherapies | — | — | — | — | — | 1 | |
| FOLFIRI or FOLFOX | — | — | — | — | — | 1 | |
| FLUO+ : Intraoperative fluorescence angiography (IOFA) with indocyanine green (ICG). | — | — | — | — | — | 1 | |
| prednisone - oral corticosteroid 1mg/kg/D for 1 week | — | — | — | — | — | 1 | |
| UCPVax | — | — | — | — | — | 5 | |
| Blood sample collection | — | — | — | — | — | 2 | |
| Temozolomide | — | — | — | — | — | 2 | |
| Atezolizumab | — | — | — | — | — | 2 | |
| Regorafenib + metronomic chemotherapy | — | — | — | — | — | 1 | |
| Carboplatin | — | — | — | — | — | 1 | |
| Human Amniotic Membrane | — | — | — | — | — | 1 | |
| Cabozantinib | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 1 | |
| MP0317 + Gemcitabine + Cisplatine + Durvalumab | — | — | — | — | — | 1 | |
| Gemcitabine + Cisplatin + Durvalumab | — | — | — | — | — | 1 | |
| Sample collection | — | — | — | — | — | 1 | |
| Blood sample | — | — | — | 9 | |||
| Plasma with neutralizing autoantibodies to Type I Interferons | — | — | — | — | — | 1 | |
| Grafalon® administered during 5 consecutive days at 2 mg/kg/j | — | — | — | — | — | 1 | |
| Grafalon® administered during 5 consecutive days at 1 mg/kg/j | — | — | — | — | — | 1 | |
| Grafalon® administered during 5 consecutive days at 0,5 mg/kg/j | — | — | — | — | — | 1 | |
| intravenous or oral bone antiresorptive treatments | — | — | — | — | — | 1 | |
| Blood sampling | — | — | — | — | — | 1 | |
| Blood sample for multiplex QPCR technique | — | — | — | — | — | 1 | |
| Early initiation of dapagliflozin 10mg daily within 24h of emergency department admission | — | — | — | — | — | 1 |
Next readouts
- 2024-02-05
- 2024-11-21
- 2025-06-01
- 2025-09
- 2025-09-01
- 2025-10-31
- 2026-01-20
- 2026-06
- 2026-10
- 2027-03
Top conditions
- Breast Cancer15
- Depression9
- Cirrhosis8
- Metastatic Colorectal Cancer6
- Cancer6
- Disorder Related to Renal Transplantation6
- Palliative Care4
- Colorectal Cancer4
Frequently asked questions about Centre Hospitalier Universitaire de Besancon
- How many clinical trials does Centre Hospitalier Universitaire de Besancon have on ClinicalTrials.gov?
- Centre Hospitalier Universitaire de Besancon is listed as the lead sponsor on 445 clinical trials in ClinicalTrials.gov, 71 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Centre Hospitalier Universitaire de Besancon's trials are in Phase 3?
- 21 of Centre Hospitalier Universitaire de Besancon's trials are in Phase 3, spread across 28 active drug programs.
- What therapeutic areas does Centre Hospitalier Universitaire de Besancon focus on?
- Centre Hospitalier Universitaire de Besancon's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Depression, Cirrhosis, Metastatic Colorectal Cancer, Cancer.
- When are Centre Hospitalier Universitaire de Besancon's next clinical trial readouts?
- Centre Hospitalier Universitaire de Besancon has 10 upcoming primary-completion readouts tracked here; the soonest is “Evaluation of Medical Practice in the Management of Bone Metastases After Injectable Bone Antiresorptive Treatment, and Its Influence on Quality of Life”, expected around 2024-02-05.